NCT07422974 Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer
| NCT ID | NCT07422974 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Osijek University Hospital |
| Condition | Colorectal Carcinoma (CRC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 68 participants |
| Start Date | 2026-01-09 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 68 participants in total. It began in 2026-01-09 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective study investigates the effects of neoadjuvant therapy on endothelial function, microvascular tissue density, and tissue fibrosis in patients with colorectal cancer and their association with perioperative complications. The primary objective is to assess differences in microvascular tissue density between patients who received neoadjuvant therapy and those who did not, biomarkers, and demographic factors between patients who received neoadjuvant therapy and those who underwent surgery as initial treatment, and to compare clinical outcomes. The study will include 34 patients treated with neoadjuvant therapy and 34 patients for whom surgery is the first-line treatment. Patients will be followed until discharge from the hospital, and complications after discharge will be monitored through medical records one month after surgery.
Eligibility Criteria
Inclusion Criteria: * Adults aged ≥18 years with histologically confirmed colorectal cancer * Planned surgical treatment for colorectal cancer (either laparoscopic LPSC or open laparotomy) * Ability to understand the study protocol and provide written informed consent. * Both sexes * ASA classification II or III * Patients who received neoadjuvant therapy is investigational group and patients who did not receive neoadjuvant therapy is control group Exclusion Criteria: * Age \<18 years * Patients who are not conscious, not oriented, or unable to provide informed consent * Patients unable to understand the study protocol * Emergency surgical cases * Patients on chronic corticosteroid therapy
Contact & Investigator
Josipa Glavas Tahtler, MD
PRINCIPAL INVESTIGATOR
KBC Osijek, MEFOS
Frequently Asked Questions
Who can join the NCT07422974 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Carcinoma (CRC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07422974 currently recruiting?
Yes, NCT07422974 is actively recruiting participants. Contact the research team at glavasjosipa@yahoo.com for enrollment information.
Where is the NCT07422974 trial being conducted?
This trial is being conducted at Osijek, Croatia.
Who is sponsoring the NCT07422974 clinical trial?
NCT07422974 is sponsored by Osijek University Hospital. The principal investigator is Josipa Glavas Tahtler, MD at KBC Osijek, MEFOS. The trial plans to enroll 68 participants.